Roche: William Pao, Johannes Clevers
Roche announced that William Pao, the head of Roche Pharma Research and Early Development since 2018, will be leaving the company effective March 18. Johannes Clevers, a member of the firm's board of directors since 2019, will be taking over Pao's position, also effective March 18. Clevers will become a member of the company's enlarged Corporate Executive Committee. A successor to Clevers' board position will be announced at a later date, Roche said.
Pao joined Roche in 2014 after serving as a professor of medicine and director of the divison of hematology/oncology at Vanderbilt University, as well as the director of personalized cancer medicine at Vanderbilt-Ingram Cancer Center. He was also previously a faculty member at Memorial Sloan-Kettering Cancer Center.
Clevers is currently a professor in molecular genetics at University Utrecht and a principal investigator at both the Hubrecht Institute and the Princess Máxima Center for Pediatric Oncology.